440 results
8-K
EX-10.2
ORKA
Oruka Therapeutics Inc.
13 Sep 24
Oruka Therapeutics Announces $200 Million Private Placement
4:02pm
audit and cold comfort letters required by or incident to such performance); provided that in no event shall the Company be responsible for any
8-K
ORKA
Oruka Therapeutics Inc.
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
.
The Board has also determined that each member of the Audit Committee (as defined below) and Compensation Committee (as defined below) is independent … public accounting firm of the Company. The decision to dismiss KPMG was approved by the Audit Committee of the Board (the “Audit Committee
8-K
EX-99.2
ORKA
Oruka Therapeutics Inc.
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
statement based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB … of the Securities and Exchange Commission and the PCAOB.
We conducted our audit of this financial statement in accordance with the standards
8-K
EX-99.4
ORKA
Oruka Therapeutics Inc.
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
additional costs of operating as a public company, including audit, legal, regulatory and tax related services associated with maintaining compliance … , including increased costs of accounting, audit, legal, regulatory and tax related services associated with maintaining compliance with SEC requirements
8-K
EX-16.1
ORKA
Oruka Therapeutics Inc.
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
with the Company’s statement regarding the Audit Committee approving our dismissal, or any statements under Item 4.01 (b).
Very truly yours,
/s/ KPMG LLP
8-K
EX-14.1
2170d3h3
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
425
EX-10.1
xopxq666xdue r5bi8ja
15 Aug 24
Business combination disclosure
4:17pm
8-K
EX-10.1
61sg1m42aombt29
15 Aug 24
Entry into a Material Definitive Agreement
4:15pm
424B3
r5b5ie5e
1 Aug 24
Prospectus supplement
4:10pm
425
EX-10.2
a6gnyu521
9 Jul 24
Business combination disclosure
5:04pm
8-K
EX-10.2
h3csyyt
9 Jul 24
Entry into a Material Definitive Agreement
5:01pm